News

Ultomiris discontinued in ALS

Friday 20 August 2021
Country
United States

AstraZeneca Plc is discontinuing a Phase 3 trial of Ultomiris (ravulizumab), a newly acquired antibody therapy being investigated in amyotrophic lateral sclerosis, due to lack of efficacy. The decision was taken following a recommendation of the trial’s independent data monitoring committee. The trial did not throw up any new safety findings, the company announced on 20 August.

Patent loss hits Lundbeck

Wednesday 18 August 2021
Country
Denmark

The loss of patent protection for Northera, a core hypotension product, depressed sales at H. Lundbeck A/S in the first half year and also affected its revenue forecast for the year. Partially offsetting this were sales gains for four medicines targeting neurological disorders as healthcare activity gradually recovered from the worst of the pandemic.

Preclinical data for CV2CoV shows better response

Tuesday 17 August 2021
Country
Germany

A new version of a Covid-19 vaccine being developed by CureVac NV and GlaxoSmithKline Plc has shown an improved immune response and protection in a preclinical study, compared with an earlier version of the vaccine, the two companies announced on 16 August.

Chronic sleep disorder treatment approved

Monday 16 August 2021
Country
United States

The US Food and Drug Administration has approved a new indication for Xywav for the treatment of idiopathic hypersomnia, a chronic sleep disorder. The disorder causes people to be excessively sleepy during the day, even after a sound sleep the night before.

FDA pathway to be reviewed

Monday 16 August 2021
Country
United States

The accelerated approval pathway, a regulatory procedure used by the Food and Drug Administration to speed drugs to market that promise to treat serious medical conditions, is to be reviewed by the Office of Inspector General (OIG), the largest oversight body in the US government. Announced in early August, the review was triggered by the FDA’s accelerated approval on 7 June of Aduhelm, a treatment for Alzheimer’s disease. This decision led to the resignation of three members of an FDA advisory committee who argued that data presented in the drug’s application was inadequate.

Philip Morris wins Vectura

Saturday 14 August 2021
Country
United Kingdom

A bidding contest between Philip Morris and Carlyle, a private equity firm, for ownership of Vectura Group Plc has ended with the cigarette company winning control of the UK pharma group. On 12 August, the Vectura board accepted a final offer from Philip Morris of 165 pence per share to acquire the company, giving a total enterprise value of £1.1 billion.

Mission achieves milestone

Saturday 14 August 2021
Country
United Kingdom

Mission Therapeutics Ltd has reached an important threshold in a three-year old collaboration with AbbVie Inc aimed at degrading the toxic proteins in Alzheimer’s and Parkinson’s diseases. The event was the selection of two enzyme targets for the development of new small molecule drugs for these diseases, which are the most common neurological disorders worldwide. It triggered a $20 million milestone payment to Mission, announced on 9 August.

Evotec sets sights on royalty income

Wednesday 11 August 2021
Country
Germany

Evotec SE continued to build its global service business in the first half of 2021 with the completion of a new biologics plant in the US, ownership of an R&D site in Verona, Italy, and new and expanded partnerships with pharma companies to co-develop compounds for multiple diseases. At the end of the first half, the company had more than 130 co-owned assets in its portfolio, potentially capable of delivering income in the form of royalty payments from 2024 onwards.

Novo lifted by GLP-1 medicines

Tuesday 10 August 2021
Country
Denmark

Novo Nordisk A/S reported turnover of DKK 66.8 billion (€8.98 billion) in the first half, up by 5% from the previous year, lifted by sales of its glucagon-like peptide-1 (GLP-1) medicines for diabetes. The three medicines in this group, Rybelsus, Ozempic and Victoza, had sales of DKK 23.4 billion, or more than a third of total group revenue.

Lundbeck gains access to RNA technology

Monday 9 August 2021
Country
Denmark

H. Lundbeck A/S has entered a collaboration with a US start-up company specialising in small molecules that target RNA, as part of a drive to expand its portfolio of medicines for central nervous system disorders. The collaboration is with Rgenta Therapeutics Inc of Cambridge, Mass, US, which has technology for identifying regulatory sites in RNA that are amenable for modulation by small molecules.